Peptide and Anticoagulant Drugs Market Size

Peptide And Anticoagulant Drugs Market Analysis

The peptide and anticoagulant drugs market is projected to register a CAGR of 3.3% during the forecast period.

COVID-19 had a substantial impact on the market's growth initially. For instance, according to an article published by Frontiers in May 2022, several peptide-based vaccine candidates and drug candidates were proposed during the pandemic, which positively affected the treatment of COVID-19 infections. Thus, the pandemic had a significant impact on the market's growth. However, as the pandemic has subsided, the market is expected to have stable growth during the forecast period.

Factors such as the increasing prevalence of cancer and metabolic disorders, rising investments in the R&D of novel drugs, and technological advancements in drug development are expected to enhance the market's growth.

The rising prevalence of cancer and other metabolic disorders is a major factor driving the market's growth. For instance, as per the report published by the Chinese Medical Journal in March 2022, China is experiencing a greater incidence of cancers. In 2022, there were approximately 4,820,000 new cancer cases in China, the most common being lung cancer.

According to the data published by National Cancer Center Japan in June 2022, an estimated 1,019,000 new cases of cancer were expected in Japan in 2022, out of which 158,200 new cases of colon/rectum cancer, 132,100 cases of stomach cancer, 128,800 cases of lung/trachea cancer, 96,400 cases of prostate cancer, and 95,000 cases of breast cancer were expected. Thus, the greater incidence of cancers has increased the demand for various peptide drugs to treat these diseases.

The rising R&D for novel drugs is also expected to boost market growth. For instance, according to the 2021 annual report of Pfizer Inc., the company invested USD 13,829 million in FY 2021, which increased heavily compared to USD 9,343 million in the previous year. As per a press release published in April 2022 by Biocon Biologics Limited, a subsidiary of biopharmaceutical market player Biocon, expects its R&D investment to increase heavily by 10-15% in FY 2023, as the company is advancing its pipeline of novel drugs to drive future growth.

The rising developments by major market players are also expected to enhance market growth. For instance, in June 2021, the Janssen Pharmaceutical Companies of Johnson & Johnson announced that the US FDA approved two pediatric indications for XARELTO (rivaroxaban), an oral anticoagulant drug. The new indications are for treating venous thromboembolism (VTE, or blood clots) and reducing the risk of recurrent VTE in patients from birth to less than 18 years after at least five days of initial parenteral (injected or intravenous) anticoagulant treatment.

Factors such as the increasing prevalence of cancer and metabolic disorders, rising investments in the R&D of novel drugs, and technological advancements in drug development are expected to enhance the market's growth. However, the high cost of developing drugs and stringent government regulations are expected to hinder this growth.